Tenmile — 2024 Investments

4 investments dated 2024 · listed companies and verified rows first · show all

Aravaxaravax.com.au inJan 2024 · $66M✓ verified

Aravax is a clinical-stage biotechnology company developing next-generation immunotherapies to treat food allergies.

BiotechHealthtechMedical DevicesMelbourne, AU

Co-investorsBreakthrough Victoria Novartis Venture Fund UniSeed Pty Ltd.

Revagenixrevagenix.com inJan 2024✓ verified

Revagenix is a precision-therapeutics company that develops drugs for serious chronic diseases, starting from the underlying biology and unmet clinical needs.

BiotechDeep TechHealthtechMedical Devices

Ryan Cirz(Co-founder & CEO)in Andrew McCandlish(Co-founder & COO)inPeter Smith(Chief Scientific Officer)inDaniel Cloutier(VP, Development)in

Co-investorsNovo Holdings

LimmaTech Biologicslmtbio.com inFeb 2024acquired by Lilly

LimmaTech develops vaccine technologies and programs designed to combat antimicrobial-resistant pathogens and prevent severe infections.

AI & Machine LearningBiotechHealthtechMedical Devices

Co-investorsAdjuvant Capital Andera Partners Novo Holdings

Psylopsylo.bioMay 2024

Sydney, Nsw

Joshua Ismin(Executive Officer, Director)Samuel Banister(Director)

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.